4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

TARGETED THERAPIES

  • Targeted therapies have an outstanding benefit-to-risk ratio on various diseases compared to non-specific therapies

  • Modern immunology offers new ways of treating cancers with vaccines 
     

  • Oncolytic viruses are the potent anti-cancer agents with the first product on the market T-VEC (Amgen)

THERAPEUTIC AREAS

  • Various cancer types

  • Infectious disease

  • Autoimmune disease

  • Rare genetic diseases